Building Commercial Conviction Before Launch: Interview with SetPoint Medical CEO Murthy Simhambhatla

Building and commercializing novel medical technology requires long-term strategic foresight, deep clinical conviction, and a clear health economic value proposition. Murthy Simhambhatla, CEO of SetPoint Medical, emphasizes that startups must visualize their commercial endgame years in advance to guide early-stage development. Success hinges on rigorous scientific validation and addressing significant unmet needs, such as the high costs and side effects associated with traditional immunosuppressive drugs for autoimmune conditions. By utilizing an in-house reimbursement hub, companies can streamline patient access, collect critical data for forecasting, and provide a superior user experience. SetPoint’s approach to vagus nerve stimulation for rheumatoid arthritis demonstrates this model, achieving a 75% drug-avoidance rate in trials and projecting $350,000 in lifetime savings per patient. This focus on quantifiable economic benefits, rather than just clinical efficacy, is essential for securing payer support and achieving long-term market adoption.